Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode for the week ended 26 June.

On the agenda this time are Pfizer Inc. and Sanofi’s coronavirus development plans and policies, what increased use of dexamethasone might mean for Indian pharma, Boehringer Ingelheim International GmbH’s M&A strategy, and an infographic on the state of global biopharma R&D.

Stories mentioned in this episode:

(Also see "Pfizer’s Bourla On COVID-19 Vaccine: "There Is No ROI That Will Drive Our Decision"" - Scrip, 22 Jun, 2020.)

(Also see "Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy" - Scrip, 23 Jun, 2020.)

(Also see "Is Dexamethasone The Next HCQ For Indian Pharma?" - Scrip, 19 Jun, 2020.)

(Also see "Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire" - Scrip, 19 Jun, 2020.)

(Also see "The 2020 Worldwide Pharma & Biotech Industry R&D Scene" - Scrip, 24 Jun, 2020.)



Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts